Ouattara Amed, Andronescu Liana R, Adams Matthew, Sharma Ankur, Nakajima Rie, Jain Aarti, Taghavian Omid, Jasinskas Algis, Felgner Philip L, Mathanga Don P, Chinkhumba Jobiba, Laufer Miriam K, Travassos Mark A
Malaria Research Program, Center for Vaccine Development and Global Heath, School of Medicine, University of Maryland, Baltimore, Maryland, USA.
Vaccine Research and Development Center, Department of Physiology and Biophysics, School of Medicine, University of California, Irvine, Irvine, California, USA.
Open Forum Infect Dis. 2025 Jan 23;12(2):ofaf037. doi: 10.1093/ofid/ofaf037. eCollection 2025 Feb.
While sulfadoxine-pyrimethamine has been the primary drug in intermittent preventive treatment in pregnancy, dihydroartemisinin-piperaquine (DP) is being considered as an alternative. DP may lead to lower antimalarial antibodies in the mother, resulting in higher risk of malaria in infancy. We probed cord blood sera collected from women enrolled in a clinical trial of sulfadoxine-pyrimethamine vs DP on a protein microarray containing diverse erythrocyte membrane proteins 1 to measure the impact of intermittent preventive treatment in pregnancy on proteins associated with malaria disease susceptibility. These results suggest that effective maternal malaria prevention may not alter the susceptibility of infants to malaria.
虽然周效磺胺-乙胺嘧啶一直是孕期间歇性预防治疗的主要药物，但双氢青蒿素-哌喹（DP）正被视为一种替代药物。DP可能会使母亲体内的抗疟抗体水平降低，从而导致婴儿期患疟疾的风险更高。我们在一个包含多种红细胞膜蛋白1的蛋白质微阵列上，检测了参与周效磺胺-乙胺嘧啶与DP对比临床试验的女性的脐带血血清，以衡量孕期间歇性预防治疗对与疟疾易感性相关蛋白质的影响。这些结果表明，有效的孕产妇疟疾预防措施可能不会改变婴儿对疟疾的易感性。
